Key result
Levosimendan offers similar acute heart failure benefits in Chinese patients as seen in global trials.
Why the study?
Levosimendan has recently become available in China after two decades of clinical use globally for acute heart failure, prompting an examination of whether clinical benefits established worldwide will accrue to Chinese patients.
Does levosimendan have similar efficacy and safety profiles in Chinese patients compared to European patients with acute heart failure?
Does levosimendan have similar efficacy and safety profiles in Chinese patients compared to European patients with acute heart failure?
Evidence from European trials of levosimendan in acute heart failure is likely applicable to Chinese patients.
Answers are grounded in this paper and cite their sources.
Supports applicability of global levosimendan data to Chinese acute HF; leaves open prospective local validation.
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the profile of levosimendan in clinical trials conducted inside and outside China and grouped the findings under six headings: effects on haemodynamics, effects on natriuretic peptides, effect on symptoms of heart failure, renal effects, effect on survival, and safety profile. Their conclusions are that under each of these headings there are reasonable grounds to expect that the effects and clinical benefits established in trials and with wider clinical use in Europe and elsewhere will accrue also to Chinese patients. Therefore, the authors are confident that global experience with levosimendan provides a reliable guide to its optimal use and likely therapeutic effects in patients in China.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2021) conducted a review in Acute heart failure. Levosimendan was evaluated. Levosimendan is expected to provide similar clinical benefits, including effects on hemodynamics, survival, and safety, for acute heart failure in Chinese patients as established in global trials.
Synapse has enriched 10 related papers. Consider them for comparative context: